Salarius Pharmaceuticals Inc (NAS:SLRX)
$ 1.67 0.0065 (0.39%) Market Cap: 2.41 Mil Enterprise Value: -558,000.00 PE Ratio: 0 PB Ratio: 0.82 GF Score: 29/100

Salarius Pharmaceuticals Inc Asset Acquisition Agreement with DeuteRx LLC - M&A Call Transcript

Jan 13, 2022 / 01:30PM GMT
Release Date Price: $97.58 (-0.93%)
Operator

Good day and welcome to the Salarius Pharmaceuticals Oncology Pipeline Expansion conference call. (Operator Instructions) As a reminder, this call may be recorded. I would now like to turn the call over to [Jason Landa], (inaudible) Strategic Advisors (inaudible).

Unidentified Company Representative Salarius Pharmaceuticals;Company Representative

Good morning and thank you for joining Salarius Pharmaceuticals on today's conference call. Earlier this morning, Salarius Pharmaceuticals issued a press release detailing a cash and stock transaction with DeuteRx LLC for the acquisition of a protein degradation portfolio, which we encourage listeners to read.

The press release can be found in the news section of SalariusPharma.com. Salarius also filed an 8-K this morning, which is available on SalriusPharma.com and SEC.gov.

Before beginning the call, I would like to make the following statement, today, we'll be making certain forward looking statements about operating metrics, future expectations, plans, events and circumstances, including

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot